BDUUY Quote, Financials, Valuation and Earnings

Bumrungrad Hospital PCL has a net margin of 15.81% compared to Bangkok Dusit Medical Services PCL's net margin of 29.4%. Bangkok Dusit Medical Services PCL's return on equity of 15.75% beat Bumrungrad Hospital PCL's return on equity of 29.91%.

Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand Bumrungrad Hospital PCL has an analysts' consensus of -- which suggests that it could fall by --. Given that Bangkok Dusit Medical Services PCL has higher upside potential than Bumrungrad Hospital PCL, analysts believe Bangkok Dusit Medical Services PCL is more attractive than Bumrungrad Hospital PCL.

Bangkok Dusit Medical Services PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Bumrungrad Hospital PCL has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.47 per share corresponding to a yield of 2.78%. Bumrungrad Hospital PCL offers a yield of 1.86% to investors and pays a quarterly dividend of $0.09 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. Bumrungrad Hospital PCL pays out 52.75% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bangkok Dusit Medical Services PCL quarterly revenues are $805.5M, which are larger than Bumrungrad Hospital PCL quarterly revenues of $190.3M. Bangkok Dusit Medical Services PCL's net income of $127.4M is higher than Bumrungrad Hospital PCL's net income of $55.9M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 28.07x while Bumrungrad Hospital PCL's PE ratio is 31.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 4.20x versus 9.41x for Bumrungrad Hospital PCL. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of 15.81% compared to Bangkok Dusit Medical Services PCL's net margin of --. Bangkok Dusit Medical Services PCL's return on equity of 15.75% beat CEL-SCI's return on equity of --.

Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 3601.99%. Given that CEL-SCI has higher upside potential than Bangkok Dusit Medical Services PCL, analysts believe CEL-SCI is more attractive than Bangkok Dusit Medical Services PCL.

Bangkok Dusit Medical Services PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.

Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.47 per share corresponding to a yield of 2.78%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bangkok Dusit Medical Services PCL quarterly revenues are $805.5M, which are larger than CEL-SCI quarterly revenues of --. Bangkok Dusit Medical Services PCL's net income of $127.4M is higher than CEL-SCI's net income of -$7.1M. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 28.07x while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 4.20x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

NewGenIvf Group has a net margin of 15.81% compared to Bangkok Dusit Medical Services PCL's net margin of --. Bangkok Dusit Medical Services PCL's return on equity of 15.75% beat NewGenIvf Group's return on equity of --.

Bangkok Dusit Medical Services PCL has a consensus price target of --, signalling downside risk potential of --. On the other hand NewGenIvf Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Bangkok Dusit Medical Services PCL has higher upside potential than NewGenIvf Group, analysts believe Bangkok Dusit Medical Services PCL is more attractive than NewGenIvf Group.

Bangkok Dusit Medical Services PCL has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NewGenIvf Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bangkok Dusit Medical Services PCL has a quarterly dividend of $0.47 per share corresponding to a yield of 2.78%. NewGenIvf Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bangkok Dusit Medical Services PCL pays 69.55% of its earnings as a dividend. NewGenIvf Group pays out -- of its earnings as a dividend. Bangkok Dusit Medical Services PCL's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bangkok Dusit Medical Services PCL quarterly revenues are $805.5M, which are larger than NewGenIvf Group quarterly revenues of --. Bangkok Dusit Medical Services PCL's net income of $127.4M is higher than NewGenIvf Group's net income of --. Notably, Bangkok Dusit Medical Services PCL's price-to-earnings ratio is 28.07x while NewGenIvf Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bangkok Dusit Medical Services PCL is 4.20x versus -- for NewGenIvf Group. Usually stocks with elevated PS ratios are considered overvalued.